Stay updated on Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now displays Revision: v3.5.0 and no longer shows Revision: v3.4.3.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page update shows a revision from v3.4.1 to v3.4.2. No substantive changes to study content or key details such as eligibility criteria or outcomes are evident.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision: v3.4.1 was added and v3.4.0 removed; this appears to be a version-label update with no substantive changes to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check68 days agoChange DetectedAdded Assuntina Sacco, MD as a study contact and removed Ezra Cohen, MD; updated QC status to 'Last Update Submitted that Met QC Criteria' with revision to v3.4.0. Introduced a new Show glossary option and updated metadata entries including 2026-01-28, 2026-01-26, and No FEAR Act Data.SummaryDifference0.5%

- Check82 days agoChange DetectedA minor revision update is shown: Revision: v3.3.4 has been added (replacing v3.3.3), and it does not affect substantive content on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.